skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Febuxostat (Code C65629)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Febuxostat

Definition: An orally available, non-purine inhibitor of xanthine oxidase with uric acid lowering activity. Upon oral administration, febuxostat selectively and noncompetitively inhibits the activity of xanthine oxidase, an enzyme that converts oxypurines, including hypoxanthine and xanthine, into uric acid. By inhibiting xanthine oxidase, uric acid production is reduced and serum uric acid levels are lowered. Febuxostat may provide protection against acute renal failure caused by the excessive release of uric acid that occurs upon massive tumor cell lysis resulting from the treatment of some malignancies.

Label: Febuxostat

NCI Thesaurus Code: C65629 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C0249529  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
2-(3-Cyano-4-(2-methylpropoxy)phenyl)-4-methylthiazole-5-carboxylic Acid
TMX 67

External Source Codes: 
CAS Registry Number 144060-53-7 (see NLM ChemIDplus info)
FDA UNII Code 101V0R1N2E
ChEBI ID CHEBI:45943 (see ChEBI info)
PDQ Closed Trial Search ID 743107
PDQ Open Trial Search ID 743107 (check for NCI PDQ open clinical trial info)
PubMedID Primary Reference 16339094 (see PubMed Primary Reference info)
UMLS CUI C0249529

Other Properties:
     Name Value (qualifiers indented underneath)
Chemical_Formula C16H16N2O3S
code C65629
Contributing_Source FDA
Legacy_Concept_Name Febuxostat
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom